Emergent BioSolutions (NYSE:EBS) Now Covered by HC Wainwright

HC Wainwright assumed coverage on shares of Emergent BioSolutions (NYSE:EBS) in a research report sent to investors on Monday morning, Marketbeat reports. The brokerage issued a buy rating and a $15.00 target price on the biopharmaceutical company’s stock.

Several other equities research analysts have also issued reports on EBS. Benchmark raised their price target on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Rodman & Renshaw reissued a “buy” rating and issued a $16.00 target price on shares of Emergent BioSolutions in a research report on Friday, September 13th. Finally, StockNews.com cut Emergent BioSolutions from a “buy” rating to a “hold” rating in a research report on Saturday.

Emergent BioSolutions Price Performance

EBS opened at $9.25 on Monday. Emergent BioSolutions has a fifty-two week low of $1.42 and a fifty-two week high of $15.10. The firm has a 50-day moving average of $9.19 and a 200 day moving average of $8.91. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. The firm has a market cap of $501.20 million, a P/E ratio of -2.26 and a beta of 1.59.

Institutional Trading of Emergent BioSolutions

Institutional investors have recently added to or reduced their stakes in the stock. SeaCrest Wealth Management LLC grew its position in shares of Emergent BioSolutions by 3.2% during the 3rd quarter. SeaCrest Wealth Management LLC now owns 118,700 shares of the biopharmaceutical company’s stock valued at $991,000 after purchasing an additional 3,705 shares in the last quarter. Meeder Asset Management Inc. purchased a new position in Emergent BioSolutions during the second quarter worth about $41,000. Verus Capital Partners LLC bought a new position in Emergent BioSolutions in the 2nd quarter worth about $68,000. Stifel Financial Corp purchased a new stake in shares of Emergent BioSolutions in the 3rd quarter valued at about $96,000. Finally, FORA Capital LLC bought a new stake in shares of Emergent BioSolutions during the 3rd quarter valued at about $103,000. Hedge funds and other institutional investors own 78.40% of the company’s stock.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.